ESTRO 2024 - Abstract Book

S2275

Clinical - Upper GI

ESTRO 2024

median PFS in patients who completed CRT were 18.6 months and 13.5 months, respectively. OS, PFS, LPFS and MFS at one-year were 87.6%, 59.3%, 81.5% and 69%, respectively. Other survival rates are listed in Table 1. Resected patients demonstrated significantly longer median OS compared to non-resected patients (28.2 months vs. 13.2 months, p=0.004). The median PFS for resected patients was 17.5 months compared to 9.5 months for non-resected patients (p=0.001). Treatment-related grade 3 to 4 toxicities included piastrinopenia (29.4%) neutropenia (5.7%), nausea and vomiting (5.7%).

Figure 1.

Table 1.

Conclusion:

FOLFIRINOX followed by long-course CRT in borderline resectable and locally advanced unresectable PDAC resulted in high rates of R0 resection and prolonged median PFS and median OS.

Keywords: Pancreatic cancer, neoadjuvant, radio-chemotherapy